Key HighlightsBTIG Research increased its price target on Tempus AI to $80 from $70 while reaffirming its Buy rating, propelling shares up 6.9% to $66.21The rally gained additional momentum from a breakthrough cancer trial involving Merck and Moderna’s mRNA treatment, which relies on Personalis’ sequencing technologyLast month, Tempus AI announced plans to acquire Personalis in a $1.5 billion deal, linking the trial success directly to TEM’s strategic expansionSecond-quarter results exceeded forecasts: adjusted EPS loss of $0.04 compared to consensus estimate of -$0.14, while revenue reached $382.49 million, marking 21.6% annual growthWall Street consensus stands at Hold with a mean price target of $65.69; analyst ratings include nine Buys, six Holds, and two SellsShares of Tempus AI (TEM) advanced 6.9% to reach $66.21 on Thursday following a bullish price target revision from BTIG Research, which increased its projection from $70 to $80 while maintaining a Buy recommendation. Trading activity was robust, with more than 4.5 million shares exchanged by midday.Tempus AI, Inc., TEMThe healthcare AI company had settled at $61.25 in the previous trading session, marking Thursday’s surge as among its most impressive single-day performances in recent trading periods.The upward momentum stemmed from more than just the analyst recommendation. Market participants are drawing connections between a pivotal clinical trial outcome and Tempus AI’s planned $1.5 billion takeover of Personalis.Merck and Moderna unveiled Phase 3 data on Wednesday for intismeran autogene, a personalized mRNA cancer treatment administered alongside Keytruda. The INTerpath-001 study demonstrated that the therapy combination enhanced recurrence-free survival among melanoma patients following surgical resection.This marked the inaugural successful Phase 3 outcome for an individualized mRNA-based oncology therapy.Moderna leverages Personalis’ sequencing technology to examine tumor samples and pinpoint the precise neoantigens required for each customized treatment dose. This relationship drew Tempus AI directly into market discussions.Tempus AI had established an earlier collaboration with Personalis focused on commercializing minimal residual disease diagnostics. The healthcare technology firm subsequently unveiled its intention last month to acquire Personalis in its entirety for $1.5 billion.Strong Quarterly PerformanceTempus AI released its latest quarterly financial report on July 30. The firm delivered an adjusted per-share loss of $0.04, outperforming the Street consensus of -$0.14 by $0.10.Top-line revenue totaled $382.49 million, surpassing analyst projections of $379.69 million. This figure reflected 21.6% year-over-year expansion.In the comparable quarter one year earlier, the company recorded a $0.22 per-share loss. The business continues to operate with a negative net margin of 17.77% and a negative return on equity of 50.28%.Wall Street analysts collectively forecast Tempus AI will report a full-year per-share loss of $1.38.Wall Street SentimentApart from BTIG, analyst opinions on TEM remain divided. Piper Sandler reduced its price objective from $58 to $56 on August 4, maintaining a neutral stance. Guggenheim elevated its target to $65 with a Buy designation in July.Wolfe Research initiated coverage in June with a peer perform rating. Weiss Ratings adjusted the stock from sell (e+) to sell (d-) in August.Overall, nine analysts assign TEM a Buy rating, six recommend Hold, and two advise Sell. The consensus recommendation is Hold, with a mean price objective of $65.69.Insider transactions have been notable. CFO James Rogers divested $634,095 in shares during June. CEO Ryan Fukushima sold stock valued at $1.91 million in July. Throughout the past 90 days, company insiders have collectively sold $33.26 million in equity.At its current level of $66.21, TEM is positioned above both its 50-day moving average of $52.10 and its 200-day moving average of $51.16.The post Tempus AI (TEM) Stock Surges 7% Following Price Target Hike and Personalis Deal Spotlight appeared first on Blockonomi.